Logo

Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancer

Share this

Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancer

Shots:

  • The P-III SEQUOIA study involves assessing of Pegilodecakin + Folfox (folinic acid- 5-FU- oxaliplatin) vs Folfox as monothx. in 567 patients with metastatic adenocarcinoma of the pancreas with diseases progression on one prior gemcitabine-containing regimen
  • The P-III SEQUOIA study did not meet its 1EPs of overall survival. Lilly gained Pegilodecakin following the acquisition of ARMO BioSciences in Jun’2018
  • Pegilodecakin is a pegylated IL-10- stimulating the body's natural defenses against cancer and expands tumor-attacking T cells and has shown clinical activity as monothx. or in combination with CT & with checkpoint inhibitor across multiple cancer indications in P-I/Ib IVY study

Click here to­ read full press release/ article | Ref: Eli Lilly | Image:FinChannel


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions